{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicnedhe3q6vdwaakoyr2gnvhbktx3zqit6zaadmoojl7odeohmvxy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnihygvjqo72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaygqgwyo7ged2iul2twrrqqv7khmn5is5g7f7rxxzj63wyrlk47q"
    },
    "mimeType": "image/jpeg",
    "size": 766457
  },
  "path": "/news/2026-06-combination-people-relapsed-acute-myeloid.html",
  "publishedAt": "2026-06-04T15:40:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML). The findings, published in the journal Blood, show encouraging results from a three-drug combination therapy in patients whose leukemia has returned or not responded to prior treatment.",
  "title": "New targeted combination in people with relapsed acute myeloid leukemia shows promise"
}